INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline
21. Januar 2025 08:33 ET
|
Berger Montague
PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (NASDAQ: REGN). The lawsuit...
NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline
17. Januar 2025 08:33 ET
|
Berger Montague
PHILADELPHIA, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the...
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
13. Januar 2025 06:30 ET
|
Regeneron Pharmaceuticals, Inc.
Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
13. Januar 2025 06:05 ET
|
Regeneron Pharmaceuticals, Inc.
The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers)...
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
10. Januar 2025 17:55 ET
|
DiCello Levitt LLP
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ:...
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
16. Dezember 2024 16:30 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI...
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
03. Dezember 2024 05:00 ET
|
Medigene AG
Payment triggered by development milestone achieved by Regeneron’s collaborator in China, JW TherapeuticsProgresses first clinical use of Medigene’s End-to-End Platform to generate potentially...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
15. November 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by...
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
24. Oktober 2024 08:00 ET
|
Regeneron Pharmaceuticals, Inc.
Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support U.S. regulatory resubmission by year-end; if...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
11. September 2024 01:04 ET
|
Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...